首页 | 本学科首页   官方微博 | 高级检索  
     

5-Fu联合HER家族靶向药物对食管癌细胞增殖影响
引用本文:许双塔, 许建华, 郑正荣, 赵清泉. 5-Fu联合HER家族靶向药物对食管癌细胞增殖影响[J]. 中国公共卫生, 2014, 30(2): 231-233. DOI: 10.11847/zgggws2014-30-02-33
作者姓名:许双塔  许建华  郑正荣  赵清泉
作者单位:1.福建医科大学附属第二医院肿瘤科, 福建 泉州 362000
基金项目:福建省教育厅科技项目(B类JA08086);泉州市优秀人才培养专项经费(08A19);泉州市财政局;科技局技术研究与开发项目(2009Z16)
摘    要:目的观察常规化疗药物联合表皮长因子受体(EGFR)靶向药物C225及人表皮生长因子受体-2(HER2)靶向药物trastuzumab对食管鳞状细胞癌细胞株HE-2增殖影响。方法常规化疗药物5-Fu分别与C225及trastuzumab联合应用于食管鳞状细胞癌细胞株HE-2,采用噻唑蓝法以及流式细胞仪检测不同处理组的抗肿瘤效果。结果5-Fu 联合C225作用24、48 h时,HE-2细胞增殖抑制率分别为(45.29±0.16)%、(70.63±0.10)%,明显高于5-Fu联合trastuzumab的细胞增殖抑制率(33.02±0.19)%、(50.08±0.20)%,差异有统计学意义(P<0.05);5-Fu 联合C225作用24、48 h时,HE-2细胞凋亡率分别为(15.47±1.62)%、(26.89±1.12)%;明显高于5-Fu联合trastuzumab的细胞凋亡率(7.34±0.88)%、(15.56±0.97)%,差异有统计学意义(P<0.05)。结论EGFR信号通路上的靶向治疗药物C225可以增加5-Fu抗食管鳞状细胞癌作用。

关 键 词:5-Fu  Her家族  靶向治疗  食管鳞状细胞癌
收稿时间:2013-08-19

Influence of 5-FU joint HER family targeted drugs on proliferation of esophageal squamous carcinoma cell
XU Shuang-ta, XU Jian-hua, ZHENG Zheng-rong.et al, . Influence of 5-FU joint HER family targeted drugs on proliferation of esophageal squamous carcinoma cell[J]. Chinese Journal of Public Health, 2014, 30(2): 231-233. DOI: 10.11847/zgggws2014-30-02-33
Authors:XU Shuang-ta  XU Jian-hua  ZHENG Zheng-rong.et al
Affiliation:1.Department of Oncology, Second Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province 362000, China
Abstract:ObjectiveTo observe the influence of conventional chemotherapy drugs combined with epidermal growth factor receptor (EGFR) targeted drug C225 and human epidermal growth factor receptor-2 (HER2) targeted drug trastuzumab on proliferation of squamous cell carcinoma of the esophagus HE-2 cell line.MethodsMethyl thiazolyl tetrazolium bromide (MTT) assay and flow cytometry were applied to detect the effects of fluorourcil (5-FU) combined with C225 or 5-FU combined with trastuzumab on the proliferation of HE-2 cells.ResultsThe in vitro experiments showed that after the treatments of 5-Fu combined with C225 for 24 hours and 48 hours,the inhibition rate of HE-2 cell proliferation was 45.29±0.16 and 70.63±0.10,significantly higher than those of 5-Fu combined with trastuzumab(33.02±0.19 and 50.08±0.20) (P<0.05 for all).With the treatment of 5-Fu combined with C225 for 24 hours and 48 hours,the apoposis rate of HE-2 cells was 15.47±1.62% and 26.89±1.12%,significantly higher than those of treatment of 5-FU combined with trastuzumab (7.34±0.88% and 15.56±0.97%) (P <0.05 for all).ConclusionThe targeted drug C225 combined with 5-FU for EGFR pathway shows a synergistic effect on inhibition of the proliferation in HE-2 cells and the signal pathway of EGFR could be as a target for the treatment of human esophageal carcinoma.
Keywords:5-FU  Her family  targeted therapy  squamous esophageal carcinoma
点击此处可从《中国公共卫生》浏览原始摘要信息
点击此处可从《中国公共卫生》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号